Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Roles of Ccr10/Ccl27–Ccl28 Axis in Tumour Development: Mechanisms, Diagnostic and Therapeutic Approaches, and Perspectives Publisher Pubmed



Terefe EM1 ; Opulencia MJC2 ; Rakhshani A3 ; Ansari MJ4 ; Sergeevna SE5 ; Awadh SA6 ; Polatova DSH7 ; Abdulkadhim AH8 ; Mustafa YF9 ; Kzar HH10 ; Algazally ME11 ; Kadhim MM12, 13, 14 ; Taherian G15
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Pharmacy and Health Science, United States International University, Nairobi, Kenya
  2. 2. College of Business Administration, Ajman University, Ajman, United Arab Emirates
  3. 3. Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
  5. 5. National Research Ogarev Mordovia State University, 68, Bolshevitskaya str., Saransk, 430005, Russian Federation
  6. 6. Department of Anesthesia Techniques, Al-Mustaqbal University College, Hillah, Iraq
  7. 7. Department of Oncology and Medical Radiology, Tashkent State Dental Institute, Tashkent, Uzbekistan
  8. 8. Department of Computer Engineering, Technical Engineering College, Al-Ayen University, Thi-Qar, Iraq
  9. 9. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq
  10. 10. Veterinary Medicine College, Al-Qasim Green University, Al-Qasim, Iraq
  11. 11. College of Medicine, University of Al-Ameed, Karbala, Iraq
  12. 12. Department of Dentistry, Kut University College, Kut, 52001, Iraq
  13. 13. College of Technical Engineering, The Islamic University, Najaf, Iraq
  14. 14. Department of Pharmacy, Osol Aldeen University College, Baghdad, Iraq
  15. 15. Halal Research Center of IRI, FDA, Tehran, Iran

Source: Expert Reviews in Molecular Medicine Published:2022


Abstract

Cancer is now one of the major causes of death across the globe. The imbalance of cytokine and chemokine secretion has been reported to be involved in cancer development. Meanwhile, CC chemokines have received considerable interest in cancer research. CCR10, as the latest identified CC chemokine receptor (CCR), has been implicated in the recruitment and infiltration of immune cells, especially lymphocytes, into epithelia such as skin via ligation to two ligands, CCL27 and CCL28. Other than homoeostatic function, several mechanisms have been shown to dysregulate CCR10/CCL27–CCL28 expression in the tumour microenvironment. As such, these receptors and ligands mediate T-cell trafficking in the tumour microenvironment. Depending on the types of lymphocytes recruited, CCR10/CCL27–CCL28 interaction has been shown to play conflicting roles in cancer development. If they were T helper and cytotoxic T cells and natural killer cells, the role of this axis would be tumour-suppressive. In contrast, if CCR10/CCL27–CCL28 recruited regulatory T cells, cancer-associated fibroblasts or myeloid-derived suppressor cells, it would lead to tumour progression. In addition to the trafficking of lymphocytes and immune cells, CCR10 also leads to the migration of tumour cells or endothelial cells (called angiogenesis and lymphangiogenesis) to promote tumour metastasis. Furthermore, CCR10 signalling triggers tumour-promoting signalling such as PI3K/AKT and mitogen-activated protein kinase/extracellular signal-regulated kinase, resulting in tumour cell growth. Since CCR10/CCL27–CCL28 is dysregulated in the tumour tissues, it is suggested that analysis and measurement of them might predict tumour development. Finally, it is hoped using therapeutic approaches based on this axis might increase our knowledge to overcome tumour progression. © The Author(s), 2022.